Match!
Ulrik Lassen
Rigshospitalet
CancerPathologyOncologyBevacizumabMedicine
194Publications
28H-index
3,531Citations
What is this?
Publications 211
Newest
#1Shivaani Kummar (Stanford University)H-Index: 37
#2Cornelis M. van Tilburg (DKFZ: German Cancer Research Center)H-Index: 4
Last. Ulrik LassenH-Index: 28
view all 19 authors...
Source
#1Antoine ItalianoH-Index: 44
#2David K. Hong (University of Texas MD Anderson Cancer Center)H-Index: 54
Last. John A. Reeves (Bayer AG: Bayer HealthCare Pharmaceuticals)
view all 14 authors...
Source
#1Alexander Drilon (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 27
#2Anna F. Farago (Harvard University)H-Index: 21
Last. Makoto TaharaH-Index: 12
view all 17 authors...
3610Background: The highly selective TRK inhibitor larotrectinib is approved for the treatment of adult and pediatric cancers that harbor NTRK gene fusions; it achieves a 79% overall response rate ...
Source
#1Caroline Even (Institut Gustave Roussy)H-Index: 12
#2Ulrik Lassen (Rigshospitalet)H-Index: 28
Last. Christophe Massard (Institut Gustave Roussy)H-Index: 43
view all 13 authors...
Background Deregulated Notch signaling is implicated in multiple cancers. The phase I trial (I6F-MC-JJCA) investigated the safety and anti-tumor activity of crenigacestat (LY3039478), a selective oral Notch inhibitor, in an expansion cohort of patients with adenoid cystic carcinoma (ACC) who received the dose-escalation-recommended phase 2 dose (RP2D), established previously (Massard C, et al., Annals Oncol 2018, 29:1911–17). Methods Patients with advanced or metastatic cancer, measurable diseas...
2 CitationsSource
#2Annie Borch (DTU: Technical University of Denmark)
Last. Inge Marie Svane (Herlev Hospital)H-Index: 36
view all 9 authors...
Abstract Background Immune checkpoint inhibitors (ICIs) have revolutionized the cancer therapeutic landscape and our perception of interactions between the immune system and tumor cells. Despite remarkable progress, disease relapse and primary resistance are not uncommon. Understanding the biological processes that tumor-infiltrating lymphocytes (TILs) undergo during ICI, how this affects the tumor microenvironment (TME) and, ultimately, clinical outcome is, therefore, necessary to further impro...
Source
#1Thomas UrupH-Index: 5
#2Linn Gillberg (UCPH: University of Copenhagen)H-Index: 14
Last. Kirsten Grønbæk (UCPH: University of Copenhagen)H-Index: 30
view all 11 authors...
Patients with recurrent glioblastoma achieving response to bevacizumab combined with chemotherapy have clinical improvement and prolonged survival. High gene expression of angiotensinogen (AGT) is associated with a poor bevacizumab response. Because AGT expression is epigenetically regulated, we aimed to investigate whether AGT promoter methylation in tumor tissue predicts response to bevacizumab combination therapy in patients with recurrent glioblastoma. The study included 159 patients with re...
Source
#1David K. Hong (University of Texas MD Anderson Cancer Center)H-Index: 54
#2N Concin (Katholieke Universiteit Leuven)H-Index: 3
Last. Robert L. Coleman (University of Texas MD Anderson Cancer Center)H-Index: 92
view all 21 authors...
Purpose: Tissue factor (TF) is a potential target in cervical cancer as it is frequently highly expressed and associated with poor prognosis. Tisotumab vedotin, a first-in-class investigational antibody-drug conjugate targeting TF, has demonstrated encouraging activity in solid tumors. Here we report data from the cervical cancer cohort of innovaTV 201 phase 1/2 study (NCT02001623). Experimental Design: Patients with recurrent or metastatic cervical cancer received tisotumab vedotin 2.0 mg/kg ev...
Source
#1Nicole Pfarr (TUM: Technische Universität München)H-Index: 17
#2Martina Kirchner (University Hospital Heidelberg)H-Index: 8
Last. Albrecht Stenzinger (University Hospital Heidelberg)H-Index: 31
view all 26 authors...
NTRK fusions involving three neurotrophic tyrosine receptor kinase genes NTRK1, NTRK2, and NTRK3 and a variety of fusion partners were identified as oncogenic drivers across many cancer types. Drugs that target the chimeric protein product require the identification of the underlying gene fusion. This advocates the diagnostic use of molecular assays ranging from fluorescence in situ hybridization (FISH) and reverse transcription polymerase chain reaction (RT-PCR)/Sanger approaches to targeted ne...
1 CitationsSource
#1Anna F. FaragoH-Index: 21
#2Shivaani KummarH-Index: 37
Last. A. DrilonH-Index: 8
view all 9 authors...
Source
1 CitationsSource
12345678910